Efficacy And Tolerability Of Second-Line Nab-Paclitaxel And Gemcitabine (Ng) After Failing First-Line Folfirinox In Patients (Pts) With Advanced Pancreatic Cancer (Apc): A Single-Institution Experience.

e15723Background: APC is incurable and has a poor prognosis. First line chemotherapy options include 5-fluorouracil, irinotecan and oxaliplatin (FOLFIRINOX) or NG. However, the optimal second-line regimen is unclear. In pts who progress on FOLFIRINOX and maintain a good performance status, NG may be a reasonable second line option. As such, we sought to: 1) describe the clinical and pathologic features of pts who received second line NG compared to pts who received second line gemcitabine (GEM) or best supportive care (BSC); 2) Evaluate the toxicity profile of NG in the second line setting; 3) determine whether a survival benefit exists with second line NG. Methods: Pts ≥18 diagnosed with APC from 2012-2016 and treated with palliative chemotherapy at CancerCare Manitoba (CCMB) were identified from the Manitoba Cancer Registry. CCMB pharmacy records identified pts who received FOLFIRINOX followed by second line NG, GEM or BSC. A retrospective analysis was performed to identify pts and treatment characteris...